MELVIN JOSE: Open Payments
NPI 1598420796 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$633 in 20 payments from 9 companies in 2025. Trend: 2023 $222 · 2024 $262 · 2025 $633
Food & beverage: $633
| Company | Payments | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 5 | $163 |
| AstraZeneca Pharmaceuticals LP | 4 | $131 |
| Astellas Pharma US Inc | 3 | $94 |
| Lilly USA, LLC | 2 | $60 |
| Incyte Corporation | 2 | $58 |
| Celgene Corporation | 1 | $34 |
| ABBVIE INC. | 1 | $33 |
| SOBI, INC | 1 | $31 |
| Merck Sharp & Dohme LLC | 1 | $29 |
Products named: CALQUENCE, REBLOZYL, Cresemba, JAYPIRCA, JAKAFI, EPKINLY, Xospata, Gamifant.
Industry payments across TX — which companies pay providers there.
